The licensing of interferon beta-1b dramatically changed the treatment of multiple sclerosis (MS) in the United States. Although it was the first therapeutic agent shown to affect the natural course of the disease, interferon beta-1b is not appropriate for all patients and is far from being a cure. Several other promising therapies now under study include immunosuppressive and immunomodulatory drugs to limit inflammation; oral administration of myelin to induce tolerance; monoclonal antibodies designed to deliver targeted immunotherapy; potassium channel blockers to facilitate conduction along demyelinated axons; and glial growth factors to promote remyelination. Clinical trials of potential therapeutic agents have proliferated in the past decade in conjunction with rapid advances in our understanding of the immunologic basis of MS. Some investigational therapies are associated with problematic toxicities, others benefit only a minority of patients, and many are still in the early stages of development Nevertheless, because current therapeutic options are limited, and because the history of MS therapy is one of disappointment and frustration, it is essential that legitimate, scientifically based advances be widely disseminated to the neurologic community. This article reviews some of the most promising current and investigational therapies for MS.
1 Antel JP, Arnason BGW. (1991) Demyelinating diseases. In: Wilson JD, et al (eds.) Harrison's Principles of Internal Medicine.12th ed.McGraw-Hill: New York: chapter 356.
2.
2 Paty DW, Li DKB, the UBC MS/MRI Study Group, the IFNB Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43: 662–667.
3.
3 Noseworthy JH et al. (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology44: 16–20.
8 Selmaj K, et al. (1991) Cytokine cytotoxicity against oligodendrocytes: apoptosis induced by lymphotoxin. J Immunol147: 1522–1529.
9.
9 Hirsch RL, Panitch HS, Johnson KP. (1985) Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol5: 386–389.
10.
10 Panitch HS, Hirsch RL, Haley AS, Johnson KP. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet1: 893–895.
11.
11 Panitch HS, Hirsch RL, Schindler J, Johnson KP. (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology37: 1097–1102.
12.
12 Ling PD, Warren MK, Vogel SN. (1985) Antagonistic effect of interferon β on the interferon-γ-induced expression of 1a antigen in murine macrophages. J Immunol135: 1857–1863.
13.
13 Barna BP, et al. (1989) Interferon-β impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol23: 45–53.
14.
14 Hartung H-P, et al. (1995) Circulating adhesion molecules and inflammatory mediators in demyelination: a review.Neurology45 (Suppl 6): S22–S32.
15.
15 Selmaj KW, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol23: 339–346.
16.
16 Olsson T. (1995) Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis.Neurology45 (Suppl 6): S11–S15.
17.
17 Schauf CL, Davis FA. (1974) Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents. J Neurol Neurosurg Psychiatry37: 152–161.
18.
18 Rasminsky M. (1973) The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol28: 287–292.
19.
19 Waxman SG. (1982) Membranes, myelin, and the pathophysiology of multiple sclerosis. N Engl J Med306: 1529–1533.
20.
20 Compston A. (1994) Future prospects for the management of multiple sclerosis.Ann Neurol36 (Suppl): S146–S150.
21.
21 Bever CT Jr. (1994) The current status of studies of aminopyridines in patients with multiple sclerosis.Ann Neurol36 (Suppl): S118–S121.
22.
22 Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. (1994) 4-aminopyridine in the treatment of patients with multiple sclerosis: long-term efficacy and safety. Arch Neurol51: 292–296.
23.
23 Rose AS, et al. (1970) Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo — final report. Neurology20: 1–59.
24.
24 Durelli L, et al. (1986) High-dose intravenous methyl-prednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations. Neurology36: 238–243.
25.
25 Millar JHD, et al. (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet2: 429–431.
26.
26 Miller H, Newell DJ, Ridley A. (1961) Multiple sclerosis: treatment of acute exacerbations with corticotrophin (ACTH). Lancer2: 1120–1122.
27.
27 Milligan NM, Newcombe R, Compston DAS. (1987) A double-blind controlled trial of high dose methylpred-nisolone in patients with multiple sclerosis: I. clinical effects. J Neurol Neurosurg Psychiatry50: 511–516.
28.
28 Troiano R, Cook SD, Dowling PC. (1987) Steroid therapy in multiple sclerosis: point of view. Arch Neurol44: 803–807.
30 Goodin DS. (1991) The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology41: 980–985.
31.
31 Goodkin DE. (1994) Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.West J Med161 (special issue): 292–298.
32.
32 Barnes MP, et al. (1985) Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry48: 157–159.
33.
33 Thompson AJ, et al. (1989) Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology39: 969–971.
34.
34 Myers L. (1992) Treatment of multiple sclerosis with ACTH and corticosteroids. In: Rudick RA, Goodkin DE (eds). Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives.Springer-Verlag: New York: pp 135–156.
35.
35 Weiner HL, Hafler DA. (1988) Immunotherapy of multiple sclerosis. Ann Neurol23: 211–222.
36.
36 Beck RW, et al. (1993) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med329: 1764–1769.
37.
37 Smith ME, Stone LA, Albert PS, et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol33: 480–489.
38.
38 Lublin FD, et al. (1996). Management of patients receiving Interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology46: 12–18.
39.
39 IFNB Multiple Sclerosis Study Group. (1993) Inteferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial.Neurology43: 655–661.
40.
40 IFNB Multiple Sclerosis Study Group, the University of British Columbia MS/MRI Analysis Group. (1995) Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology45: 1277–1285.
41.
41 Noronha A, Toscas A, Jensen MA. (1991) IFN-beta down-regulates IFN-gamma production by activated T cells in MS. Neurology41 (Suppl 1): 219 (Abstract).
42.
42 Panitch HS, Folus JS, Johnson KP. (1987) Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis. Ann Neurol22: 139 (Abstract).
43.
43 Ransohoff RM, et al. (1991) Interferon β specifically inhibits interferon γ-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J Neuroimmunol33: 103–112.
44.
44 Panitch HS, Folus JS, Johnson KP. (1989) Beta interferon prevents HLA class II antigen induction by gamma interferon in MS.Neurology39 (Suppl 1): 171 (Abstract).
45.
45 Noronha A, Toscas A, Jensen MA. (1993) Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol46: 145–154.
46.
46 Noronha A, Jensen MA, Toscas A, Sihag S. (1992) IFN-beta downregulates tumor necrosis factor release.Neurology42 (Suppl 3): 159 (Abstract).
47.
47 Noronha A, Toscas A, Jensen MA. (1990) Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol27: 207–210.
48.
48 Jacobs L, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol39: 285–294.
49.
49 Ellison GW, et al. (1989) A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology39: 1018–1026.
50.
50 Yudkin PL, et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet338: 1051–1055.
51.
51 British and Dutch Multiple Sclerosis Azathioprine Trial Group. (1988) Double-masked trial of azathioprine in multiple sclerosis. Lancet2: 179–183.
52.
52 Goodkin DE, et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol37: 30–40.
53.
53 Hauser SL, et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med308: 173–180.
54.
54 The Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet337: 441–446.
55.
55 Likosky WH, et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry54: 1055–1060.
56.
56 Weiner HL, et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology43: 910–918.
57.
57 Balow JE, et al. (1987) Lupus nephritis. Ann Intern Med106: 79–94.
58.
58 Plotz PH, et al. (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med91: 221–223.
59.
59 Casciato DA, Scott JL. (1979) Acute leukemia following prolonged cytotoxic agent therapy. Medicine58: 32–47.
60.
60 Cohen DJ, et al. (1984) Cyclosporine: a new immunosuppressive agent for organ transplantation. Ann Intern Med101: 667–682.
61.
61 Manger B, Hardy KJ, Weiss A, Stobo JD. (1986). Differential effect of cyclosporin A on activation signaling in human T cell lines. J Clin Invest77: 1501–1506.
62.
62 Kahan BD. (1989). Cyclosporine. N Engl J Med321: 1725–1739.
63.
63 Multiple Sclerosis Study Group. (1990) Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial.Ann Neurol27: 591–605.
64.
64 Kappos L, et al. (1988) Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis: results of the German multicenter study. Ann Neurol23: 56–63.
65.
65 Rudge P, et al. (1989) Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry52: 559–565.
66.
66 Sipe JC, et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet344: 9–13.
67.
67 Beutler E, et al. (1994) Marrow suppression produced by repeated doses of cladribine. Acta Haematol91: 10–15.
68.
68 Cook SD, et al. (1986) Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet1: 1405–1409.
69.
69 Cook SD, et al. (1987) Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. Ann Neurol22: 634–638.
70.
70 Panitch HS. (1992) Interferons in multiple sclerosis: a review of the evidence. Drugs44: 946–962.
71.
71 Panitch H, Milo R. (1995) Interferon therapy for multiple sclerosis. Int Multiple Sclerosis J2: 13–25.
72.
72 Knobler RL, et al. (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology34: 1273–1279.
73.
73 Camenga DL, et al. (1986) Systemic recombinant α-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol43: 1239–1246.
74.
74 Kastrukoff LF, et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. clinical and MRI evaluation. Neurology40: 479–486.
75.
75 Durelli L, et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology44: 406–413.
76.
76 Weinstock-Guttman B, et al. (1985) The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol37: 7–15.
77.
77 Johnson KP, et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology45: 1269–1276.
78.
78 Teitelbaum D, et al. (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol1: 242–248.
79.
79 Webb C, Teitelbaum D, Arnon R, Sela M. (1973) In vivo and in vitro immunologic cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol3: 279–286.
80.
80 Webb C, et al. (1976) Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry13: 333–337.
81.
81 Bornstein MB, et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med317: 408–414.
82.
82 Brosnan CF, et al. (1985) Immunogenic potentials of copolymer I in normal human lymphocytes. Neurology35: 1754–1759.
83.
83 Milo R, Panitch H. (1995) Additive effects of copolymer-1 and interferon-β-1b on the immune response to myelin basic protein. J Neuroimmunol61: 185–193.
84.
84 Bornstein MB, et al. (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology41: 533–539.
85.
85 Cohen JA, et al. (1995) Assessment of the efficacy of copolymer-1 in the treatment of multiple sclerosis by quantitative MRI. Neurology45 (Suppl 4): A418 (Abstract).
86.
86 Wolinsky JS. (1995) Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology45: 1245–1247 (Editorial).
87.
87 Wells HG. (1911) Studies on the chemistry of anaphylaxis: III. experiments with isolated proteins, especially those of the hen's egg. J Infect Dis9: 147–151.
88.
88 Weiner HL, et al. (1995) Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol12: 809–837.
89.
89 Miller A, et al. (1992) Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of TGF-β following antigen specific triggering. Proc Natl Acad Sci USA89: 421–425.
90.
90 Weiner HL, et al. (1993) Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science259: 1321–1324.
91.
91 Trentham DE, et al. (1993) Effects of oral administration of collagen on rheumatoid arthritis. Science261: 1727–1730.
92.
92 Karussis DM, et al. (1993) Inhibition of acute experimental autoimmune encephaloymyelitis by the synthetic immunomodulator Linomide. Ann Neurol34: 654–660.
93.
93 Karussis DM, et al. (1993) Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator Linomide (quinoline-3-carboxamide). Proc Natl Acad Sci USA90: 6400–6404.
94.
94 Karussis D, et al. (1995) Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: results of a double-blind placebo-controlled study with monthly MRI evaluation.Neurology45 (Suppl 4): A417.
95.
95 Moreau T, et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet344: 298–301.
96.
96 Lindsey JW, et al. (1994) Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology44: 413–419.
97.
97 Lindsey JW, et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol36: 183–189.
98.
98 Yednock TA, et al. (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature356: 63–66.
99.
99 Sherratt RM, Bostock H, Sears TA. (1980) Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres.Nature, 283: 570–572.
100.
100 Bever CT Jr, et al. (1994) The efficacy and toxicity of oral 3, 4-diaminopyridine in multiple sclerosis patients.Neurology44 (Suppl 2): A374 (Abstract).
101.
101 Bertelsmann FW, et al. (1992) A comparison between 4-aminopyridine and 3, 4-diaminopyridine in the treatment of multiple sclerosis. Ann Neurol32: 256 (Abstract).
102.
102 van Diemen HAM, et al. (1992) The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, crossover study. Ann Neurol32: 123–130.
103.
103 Bever CT Jr, et al. (1994) The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology44: 1054–1059.
104.
104 Carter JL, et al. (1993) A double-blind, placebo-controlled crossover trial of 3, 4 diaminopyridine in the symptomatic treatment of multiple sclerosis. Ann Neurol34: 272–273 (Abstract).
105.
105 Weinshenker BG, Sibley WA. (1992) Natural history and treatment of multiple sclerosis.Curr Opin Neurol Neurosurg5: 203–211.
106.
106 Bever CT Jr, et al. (1990) Preliminary trial of 3, 4-diaminopyridine in patients with multiple sclerosis. Ann Neurol27: 421–427.
107.
107 Ball AP, et al. (1979) Human botulism caused by Clostridium botulinum type e: the Birmingham outbreak. Q J Med48: 473–491.
108.
108 Grinspan IB, et al. (1994) Protein growth factors as potential therapies for central nervous system demyelinative disorders. Ann Neurol36 (Suppl): S140–S142.
109.
109 Groves AK, et al. (1993) Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature362: 453–455.
